Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Assets (2016 - 2025)

Historic Assets for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $1.0 billion.

  • Tg Therapeutics' Assets rose 7491.46% to $1.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 billion, marking a year-over-year increase of 7491.46%. This contributed to the annual value of $577.7 million for FY2024, which is 7527.69% up from last year.
  • Per Tg Therapeutics' latest filing, its Assets stood at $1.0 billion for Q3 2025, which was up 7491.46% from $702.6 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Assets registered a high of $1.0 billion during Q3 2025, and its lowest value of $193.6 million during Q4 2022.
  • Over the past 5 years, Tg Therapeutics' median Assets value was $379.6 million (recorded in 2021), while the average stood at $430.9 million.
  • Its Assets has fluctuated over the past 5 years, first surged by 43873.77% in 2021, then plummeted by 4901.02% in 2022.
  • Tg Therapeutics' Assets (Quarter) stood at $379.6 million in 2021, then crashed by 49.01% to $193.6 million in 2022, then soared by 70.27% to $329.6 million in 2023, then soared by 75.28% to $577.7 million in 2024, then surged by 77.43% to $1.0 billion in 2025.
  • Its Assets was $1.0 billion in Q3 2025, compared to $702.6 million in Q2 2025 and $656.7 million in Q1 2025.